Cardiology |
|
 |
GraftMaster® RX Coronary Stent Graft System |
Abbott Vascular Devices |
 |
A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Left Ventricular Systolic Dysfunction following Myocardial Infarction |
Armaron Bio Pty Ltd |
 |
ARTEMIS Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
AstraZeneca |
 |
Cardiovascular Inflammation Reduction Trial (CIRT): A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome |
Brigham and Women's Hospital / NIH |
 |
Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE-STEMI for Seniors) |
Duke Clinical Research Institute |
 |
Care Optimization Through Patient And Hospital Engagement Clinical Trial For Heart Failure—Connect-Hf |
Duke Clinical Research Institute (DCRI) |
 |
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Acute Coronary Syndrome (UPSTREAM): An EDBased Clinical Registry |
Hospital Quality Foundation |
 |
NJ Demonstration C-PORT Project Workscope |
Johns Hopkins Medical Institutions - clinical coordinating center |
 |
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency |
Luitpold Pharmaceuticals / Duke Clinical Research Institute |
 |
Long-term legacy effects of LDL-C lowering with alirocumab: observational follow-up of the ODYSSEY OUTCOMES study |
Sanofi R&D |
 |
Endocrinology |
|
 |
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus |
Novo Nordisk |
 |
Gastroenterology |
|
 |
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY) |
Eli Lilly and Company |
 |
An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Active Crohn’s Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study |
RedHill Biopharma Ltd. |
 |
A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn’s Disease |
RedHill Biopharma Ltd. |
 |
Infectious Diseases |
|
 |
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection |
Janssen Research & Development |
 |
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Adult Subjects Hospitalized with Respiratory Syncytial Virus |
Janssen Research & Development |
 |
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection |
Rebiotix Inc. |
 |
Efficacy, Immunogenicity, and Safety Study of Clostridiumdifficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection (Cdiffense™) |
Sanofi Pasteur Inc. |
 |
Interventional Radiology |
|
 |
MarrOwStim™ PAD Kit for the Treatment of Critical LimB IschemIa (CLI) in Subjects with Severe Peripheral ArteriaL DiseasE
(PAD) (MOBILE) |
Biomet Biologics |
 |
Tack Optimized Balloon Angioplasty Study for the Below The Knee Arteries Using the Tack Endovascular System® (TOBA II BTK) |
Intact Vascular |
 |
A Pilot Study To Investigate The Safety, Effectiveness, And Feasibility Of The Limflow Stent Graft System For Creating An Av Fistula For The Treatment Of Critical Limb Ischemia |
LimFlow, Inc. |
 |
A multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous selfexpanding
stent system in patients with symptomatic iliofemoral venous outflow obstruction. |
Medtronic Vascular Inc. |
 |
IN.PACT™ AV Access Paclitaxel-Coated PTA Balloon
Catheter (“IN.PACT™ AV Access DCB”) |
Medtronic Vascular, Inc. |
 |
TANGO: Temsirolimus adventitial delivery to improve ANGiographic Outcomes below the knee |
Mercator MedSystems, Inc. |
 |
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate
the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical
Limb Ischemia (CLI) with Minor Tissue Loss who are Unsuitable for Revascularization (PACE Study) |
Pluristem Ltd. |
 |
The Detour Ii Study - PQ Bypass System For Femoropopliteal Bypass Ii |
PQ Bypass, Inc. |
 |
The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the
SurVeil™ Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery
Compared to the Medtronic IN.PACT® Admiral Drug-Coated Balloon TRANSCEND Study |
SurModics, Inc. |
 |
Multiple Sclerosis |
|
 |
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies (AFFINITY) |
Biogen MA Inc. |
 |
A Phase Iii, Multicentre, Randomized, Parallel-Group, Double Blinded, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis |
F. Hoffmann-La Roche LTD |
 |
An Open-Label Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Relapsing Remitting Multiple Sclerosis Who Have Had A Suboptimal Response To An Adequate Course Of Disease-Modifying Treatment |
Genentech, Inc. |
 |
long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) |
Genzyme Corporation - A Sanofi Company |
 |
Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study |
MedDay Pharmaceuticals SA |
 |
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy (PASSAGE) |
Novartis Pharmaceuticals Corporation |
 |
NULLA 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsingremitting multiple sclerosis |
Novartis Pharmaceuticals Corporation |
 |
Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY). |
TG Therapeutics, Inc. |
 |
Oncology |
|
 |
Alternate approaches for clinical Stage II and III Estrogen receptor positive breast cancer neoadjuvant treatment (ALTERNATE) in postmenopausal women: a Phase III Study |
A011106/ CTSU/CIRB |
 |
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
A011401/ CTSU/CIRB |
 |
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy |
AstraZeneca Pharmaceuticals LP |
 |
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS = 50%) (KEYNOTE-598) |
Merck Sharp & Dohme |
 |
A randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclohosphamide followed by weekly Paclitaxel with or without Carboplatin for node-positive ir high-risk Node-negative invasive breast cancer |
NRG-BR003/ CTSU/CIRB |
 |
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (veliparib) in metastatic triple-negative Breast Cancer and/or BRCA mutation-associated Breast Cancer |
S1416/ CTSU/CIRB |
 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy |
TESARO, Inc. |
 |
|